Findit, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 21, 2022 at 05:04 pm
Share
Findit, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was USD 0.011283 million compared to USD 0.037619 million a year ago. Net loss was USD 0.002191 million compared to USD 0.031934 million a year ago.
For the nine months, revenue was USD 0.033245 million compared to USD 0.186734 million a year ago. Net loss was USD 0.072773 million compared to USD 0.038741 million a year ago.
BioRegenx, Inc., formerly Findit, Inc., operates as a holding company. The Company specializes in acquiring intellectual property (IP) and companies engaged in regenerative biotherapeutics and anti-aging research. Its primary focus involves acquiring and developing non-invasive medical and wellness devices capable of efficiently recording, storing, and analyzing datasets. The Companyâs patented technologies and solutions include GlycoCheck, a high-definition video imaging that analyzes five parameters of microvascular health non-invasively with an under the tongue test using patented technology; Endocalyx Pro, an all-natural, plant-based patented nutraceutical shown to restore, regenerate, and protect microvascular health. Clinically tested in multiple double-blind placebo studies, and DocSun, an artificial intelligence using three advanced facial recognition technologies that analyzes 21 vital signs and health indicators without physical contact.